See more : Surgutneftegas Public Joint Stock Company (SGGD.IL) Income Statement Analysis – Financial Results
Complete financial analysis of Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tianjin Ringpu Bio-Technology Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- JKX Oil & Gas plc (JKX.L) Income Statement Analysis – Financial Results
- f-code Inc. (9211.T) Income Statement Analysis – Financial Results
- Hangzhou Oxygen Plant Group Co.,Ltd. (002430.SZ) Income Statement Analysis – Financial Results
- Idorsia Ltd (0RQE.L) Income Statement Analysis – Financial Results
- Banque Cantonale de Genève SA (BCGE.SW) Income Statement Analysis – Financial Results
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ)
About Tianjin Ringpu Bio-Technology Co.,Ltd.
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sales of veterinary biological products, veterinary drug preparations, functional additives, and veterinary raw materials in China. The company provides vaccines and drugs for poultry, swine, and other animals; pet products comprising pet rabies inactivated vaccine, recombinant canine-a interferon, inhalation anesthetics isoflurane and sevoflurane for dogs and cats, cefquinoxime sulfate for injection for prevention and treatment of pet bacterial diseases, heart disease drugs for dogs and cats, napril chewable tablets and other products; and waterfowl products, including duck tempusu live/inactivated vaccine, gosling plague refined egg yolk antibody, duck infectious serositis inactivated vaccine, duck viral hepatitis refined egg yolk antibody, duck plague live vaccine, florfenicol soluble powder, kanamycin injection, etc. It also offers antifungal products, such as natural plant extracts, immune polysaccharides, clostridium butyricum, lactobacillus plantarum, antibacterial peptides, enzyme preparations, acidulants, etc; disinfection and cleaning products, consisting of potassium hydrogen persulfate composite powder, benzyl trimethyl ammonium chloride solution, deca methyl ammonium bromide solution, sodium dichloroisocyanurate, iodine glycerin solution, etc.; and APIs comprising tilmicosin, tilmicosin phosphate, monbutone, tidiroxine, florfenicol, vonimulin hydrochloride, gamimycin, etc. The company was founded in 1998 and is based in Tianjin, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.25B | 2.08B | 2.01B | 2.00B | 1.47B | 1.19B | 1.05B | 969.86M | 792.83M | 585.20M | 754.90M | 656.39M | 587.71M | 345.62M | 285.36M | 224.13M | 146.10M |
| Cost of Revenue | 1.13B | 1.07B | 967.37M | 919.39M | 699.16M | 593.59M | 492.10M | 413.61M | 327.19M | 237.12M | 306.88M | 273.26M | 260.43M | 100.75M | 64.82M | 59.01M | 47.47M |
| Gross Profit | 1.12B | 1.01B | 1.04B | 1.08B | 767.42M | 596.27M | 555.23M | 556.25M | 465.64M | 348.08M | 448.02M | 383.13M | 327.29M | 244.87M | 220.53M | 165.12M | 98.63M |
| Gross Profit Ratio | 49.69% | 48.44% | 51.80% | 54.04% | 52.33% | 50.11% | 53.01% | 57.35% | 58.73% | 59.48% | 59.35% | 58.37% | 55.69% | 70.85% | 77.28% | 73.67% | 67.51% |
| Research & Development | 172.94M | 132.68M | 117.69M | 111.53M | 94.79M | 80.33M | 85.30M | 76.56M | 43.89M | 37.94M | 36.49M | 23.90M | 20.10M | 14.94M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 48.56M | 43.98M | 49.13M | 56.93M | 48.68M | 43.05M | 47.45M | 44.39M | 37.23M | 24.30M | 34.43M | 38.45M | 21.12M | 16.19M | 24.77M | 17.85M | 11.11M |
| Selling & Marketing | 209.71M | 344.07M | 378.88M | 356.34M | 279.44M | 231.60M | 216.47M | 199.69M | 202.42M | 225.88M | 190.36M | 137.05M | 138.64M | 100.31M | 93.36M | 73.94M | 31.61M |
| SG&A | 258.28M | 388.05M | 428.01M | 413.27M | 328.12M | 274.64M | 263.92M | 244.08M | 239.65M | 250.18M | 224.80M | 175.49M | 159.76M | 116.50M | 118.13M | 91.79M | 42.72M |
| Other Expenses | 121.00M | 21.54M | 91.07M | 96.83M | 59.27M | 251.30K | 2.40M | 31.03M | 16.45M | 18.66M | 28.26M | 18.49M | 6.16M | 15.39M | 1.46M | 3.25M | 2.02M |
| Operating Expenses | 547.31M | 612.81M | 632.77M | 629.38M | 510.16M | 414.20M | 388.99M | 388.25M | 336.26M | 331.90M | 301.11M | 240.91M | 205.42M | 140.03M | 119.35M | 92.20M | 42.72M |
| Cost & Expenses | 1.68B | 1.69B | 1.60B | 1.55B | 1.21B | 1.01B | 881.09M | 801.86M | 663.45M | 569.01M | 607.99M | 514.18M | 465.84M | 240.78M | 184.17M | 151.21M | 90.19M |
| Interest Income | 5.61M | 11.20M | 5.80M | 3.37M | 1.69M | 1.86M | 1.26M | 840.59K | 5.33M | 9.08M | 17.82M | 24.55M | 28.15M | 5.08M | 480.85K | 0.00 | 0.00 |
| Interest Expense | 24.33M | 28.43M | 23.82M | 27.17M | 24.51M | 17.26M | 15.12M | 10.10M | 4.79M | 1.91M | 2.27M | 2.68M | 2.28M | 2.82M | -19.21K | 0.00 | 132.89K |
| Depreciation & Amortization | 144.48M | 112.03M | 87.74M | 96.63M | 92.49M | 92.84M | 91.45M | 78.21M | 50.08M | 40.73M | 34.08M | 28.32M | 21.69M | 10.05M | 8.33M | 5.34M | 3.58M |
| EBITDA | 711.43M | 553.98M | 595.35M | 634.12M | 378.86M | 277.43M | 252.05M | 267.89M | 199.10M | 82.65M | 215.34M | 209.56M | 173.80M | 133.72M | 109.51M | 78.88M | 59.82M |
| EBITDA Ratio | 31.63% | 26.34% | 30.55% | 32.36% | 28.92% | 24.30% | 26.30% | 29.34% | 25.91% | 14.49% | 29.93% | 32.65% | 30.27% | 38.70% | 39.00% | 35.41% | 41.40% |
| Operating Income | 565.23M | 416.64M | 499.36M | 513.12M | 263.07M | 161.70M | 142.08M | 149.54M | 125.28M | 20.75M | 150.74M | 159.28M | 143.66M | 103.78M | 99.88M | 72.17M | 54.77M |
| Operating Income Ratio | 25.13% | 19.99% | 24.88% | 25.65% | 17.94% | 13.59% | 13.57% | 15.42% | 15.80% | 3.55% | 19.97% | 24.27% | 24.44% | 30.03% | 35.00% | 32.20% | 37.49% |
| Total Other Income/Expenses | 1.45M | -3.66M | -11.57M | -3.34M | -3.15M | 251.30K | 2.40M | 29.70M | 16.26M | 18.53M | 29.01M | 18.48M | 32.60M | 15.33M | 1.46M | 3.25M | 2.02M |
| Income Before Tax | 566.68M | 413.81M | 487.79M | 510.92M | 259.92M | 161.95M | 144.47M | 178.45M | 141.54M | 39.29M | 178.98M | 177.76M | 149.81M | 119.11M | 101.34M | 75.42M | 56.79M |
| Income Before Tax Ratio | 25.20% | 19.85% | 24.30% | 25.54% | 17.72% | 13.61% | 13.79% | 18.40% | 17.85% | 6.71% | 23.71% | 27.08% | 25.49% | 34.46% | 35.51% | 33.65% | 38.87% |
| Income Tax Expense | 55.66M | 40.04M | 54.20M | 71.43M | 36.12M | 20.90M | 19.72M | 25.15M | 19.06M | 10.42M | 25.75M | 26.15M | 21.62M | 18.70M | 13.01M | 9.74M | 1.50M |
| Net Income | 452.94M | 346.70M | 412.78M | 398.20M | 194.36M | 118.98M | 104.90M | 132.78M | 110.31M | 27.13M | 151.96M | 144.08M | 114.09M | 82.54M | 61.50M | 43.32M | 36.96M |
| Net Income Ratio | 20.14% | 16.63% | 20.57% | 19.91% | 13.25% | 10.00% | 10.02% | 13.69% | 13.91% | 4.64% | 20.13% | 21.95% | 19.41% | 23.88% | 21.55% | 19.33% | 25.30% |
| EPS | 0.98 | 0.74 | 0.88 | 0.99 | 0.49 | 0.29 | 0.26 | 0.34 | 0.28 | 0.07 | 0.39 | 0.38 | 0.30 | 0.27 | 0.21 | 0.16 | 0.16 |
| EPS Diluted | 0.98 | 0.74 | 0.88 | 0.99 | 0.49 | 0.29 | 0.26 | 0.34 | 0.28 | 0.07 | 0.39 | 0.38 | 0.30 | 0.27 | 0.21 | 0.16 | 0.16 |
| Weighted Avg Shares Out | 463.51M | 468.02M | 466.46M | 402.47M | 397.14M | 404.49M | 404.49M | 394.25M | 389.10M | 385.63M | 389.64M | 382.98M | 385.52M | 310.02M | 289.80M | 273.84M | 228.08M |
| Weighted Avg Shares Out (Dil) | 463.51M | 468.02M | 466.46M | 402.47M | 397.14M | 404.55M | 404.53M | 394.25M | 389.10M | 385.63M | 389.64M | 382.98M | 385.52M | 310.02M | 289.80M | 273.84M | 228.08M |
Source: https://incomestatements.info
Category: Stock Reports